Definition
Psoriasis is a chronic inflammatory skin disorder affecting around 2-3% of the world’s population. It is identified as thick scaling red plaques, resulting from an unusually high rate of skin cell growth. It usually involves the skin and nails, and leads to lesions which cause itching, stinging, and pain. While the main cause of psoriasis remains uncertain, several studies have reported that it is due to autoimmunity, genetic predisposition, and environmental factors. Additionally, psoriasis may be provoked by several triggers, including trauma, obesity, infection, systemic drugs, and stress.
Latest Key Takeaways
Psoriasis is a chronic inflammatory skin disorder affecting around 2-3% of the world’s population. It is identified as thick scaling red plaques, resulting from an unusually high rate of skin cell growth. It usually involves the skin and nails, and leads to lesions which cause itching, stinging, and pain. While the main cause of psoriasis remains uncertain, several studies have reported that it is due to autoimmunity, genetic predisposition, and environmental factors. Additionally, psoriasis may be provoked by several triggers, including trauma, obesity, infection, systemic drugs, and stress.
Latest Key Takeaways
- The publisher estimates that in 2018, there were 52.2 million prevalent cases of psoriasis worldwide, and forecasts that number to increase to 55.4 million prevalent cases by 2027.
- First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.
- While the psoriasis market will see downward pressure from the arrival of biosimilars of the key marketed anti-TNF brands Enbrel and Humira, overall growth will be driven partly by the recent launch of a number of more targeted and efficacious interleukin inhibitors, expanding the market, as well as by increasing prevalence of the disease.
- Results from head-to-head studies solidly place IL-17 and IL-23 inhibitors ahead of older TNF-alpha inhibitors in terms of efficacy, while differentiating between these newer pathways may come down to speed of disease clearance and safety signals. AbbVie’s IL-23 inhibitor Skyrizi, with strong disease clearance, stands out among competitors with remarkably fast uptake on the market.
- Positive readouts from bimekizumab’s three Phase III psoriasis trials, including head-to-head comparisons against Stelara and Humira, will ensure approval of UCB’s IL-17A/F inhibitor. Unlike Novartis’s Cosentyx and Eli Lilly’s Taltz, which target IL-17A, bimekizumab neutralizes both IL-17A and IL-17F. Approval decisions for bimekizumab in the US and Europe are expected in 2021.
- Results from the Phase III POETYK-PSO trials of Bristol Myers Squibb’s TYK2 inhibitor deucravacitinib demonstrate superiority over Otezla, giving deucravacitinib an advantage in the oral treatment market in moderate-to-severe psoriasis. However, Amgen is looking to extend Otezla’s label into mild disease, which would help this product to maintain share in the psoriasis market.
- The overall likelihood of approval of a Phase I psoriasis asset is 10.9%, and the average probability a drug advances from Phase III is 75%. Psoriasis drugs, on average, take 7.7 years from Phase I to approval.
Table of Contents
OVERVIEW
DISEASE BACKGROUND
TREATMENT
EPIDEMIOLOGY
KEY REGULATORY EVENTS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
DRUG ASSESSMENT MODEL
FUTURE TRENDS
RECENT EVENTS AND ANALYST OPINION
KEY OPINION LEADER INSIGHTS
UNMET NEEDS
LIST OF FIGURES
LIST OF TABLES
